Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2021 19:22 ET | Source: VALNEVA

Valneva publie un amendement à son Document d’enregistrement universel 2020

Saint-Herblain (France), le 27 octobre 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui la publication et le dépôt auprès de...
October 26, 2021 19:22 ET | Source: VALNEVA

Valneva Publishes Amendment to 2020 Universal Registration Document

Saint Herblain (France), October 27, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the publication of an amendment filed with the French Financial...
October 26, 2021 18:44 ET | Source: VALNEVA

Valneva annonce le lancement d’un projet d’offre globale d’American Depositary Shares et d’actions ordinaires

Ne pas diffuser hors de France Saint Herblain (France), le 27 octobre 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (la “Société”), société spécialisée dans les vaccins, a annoncé...
October 26, 2021 17:59 ET | Source: VALNEVA

Valneva Announces Launch of Proposed Global Offering of American Depository Shares and Ordinary Shares

Saint Herblain (France), October 26, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, today announced its intention to issue and sell, subject to...
October 19, 2021 04:03 ET | Source: Research and Markets

Global Lyme Disease Preventive Vaccine & Shot Market Report 2021-2028 - Continuous Need for Reinventing the Drug Pipeline, Led by Bacterial Mutation and Resistance

Dublin, Oct. 19, 2021 (GLOBE NEWSWIRE) -- The "Global Lyme disease Preventive Vaccine & Shot Market Size By Type, By geographic Scope And Forecast" report has been added to...
October 18, 2021 01:00 ET | Source: VALNEVA

Valneva annonce des résultats de Phase 3 positifs pour son candidat vaccin inactivé et adjuvanté contre la COVID-19, VLA2001

VLA2001 remplit avec succès les deux principaux critères d’évaluation de l’essai Niveaux de titres d’anticorps supérieurs comparés au vaccin d’AstraZeneca AZD1222 (ChAdOx1-S)Taux de séroconversion des...
October 18, 2021 01:00 ET | Source: VALNEVA

Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001

VLA2001 successfully met both co-primary endpoints Superior neutralizing antibody titer levels compared to active comparator vaccine, AstraZeneca’s AZD1222 (ChAdOx1-S)Neutralizing antibody...
October 05, 2021 12:06 ET | Source: VALNEVA

Déclaration d’actions et de droits de vote - Situation intermédiaire au 4 octobre 2021 (et information au 30 septembre 2021)

VALNEVA Déclaration d’actions et de droits de voteSituation intermédiaire au 4 octobre 2021 (et information au 30 septembre 2021) Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain...
October 04, 2021 15:15 ET | Source: Lowey Dannenberg, P.C.

SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of Valneva SE (VALN) and Encourages Investors With More Than $50,000 in Losses to Contact the Firm

NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities...
October 04, 2021 13:00 ET | Source: VALNEVA

Valneva Announces the Cancellation of Ordinary Shares Held by the Company following Termination of its Liquidity Agreement

Saint-Herblain (France), October 4, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Management Board has decided, during a meeting today,...